ERBB2 and metastatic neoplasm: Importantly, patients in which there is conversion from a luminal subtype in the PT to the HER2-E subtype in DMs may benefit from anti-HER2 treatment, as was previously suggested for clinically HER2-negative MBC [34], again highlighting the potential importance of the molecular characterization of metastatic disease.